CoChat

Efficacy and safety of an expanded dulaglutide dose range: A phase 2, placebo‐controlled trial in patients with type 2 diabetes using metformin

Frias, Juan P., Wynne, Alan G., Matyjaszek‐Matuszek, Beata, Bartaskova, Dagmar, Cox, David A., Woodward, Brad, Li, Ying G., Tham, Lai S., Milicevic, Zvonko · 2019 · Diabetes, Obesity and Metabolism
Cited by 46

The DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.

Abstract

Aims: Dulaglutide, a once weekly GLP‐1 receptor agonist, is approved at two doses (1.5 and 0.75 mg) for treatment of type 2 diabetes (T2D). Two higher doses of dulaglutide (3.0 and 4.5 mg) were evaluated for safety and efficacy to determine whether these doses warrant further study for improved control of glucose and body weight. Materials and methods: This 18‐week, double‐blind, phase 2 trial randomized 318 patients with T2D using ≥1500 mg metformin, to receive subcutaneous injection of placebo (n = 82), dulaglutide 1.5 mg (n = 81), dulaglutide 3.0 mg (n = 79) or dulaglutide 4.5 mg (n = 76). The primary objective was superiority of dulaglutide doses over placebo in reduction of HbA1c at 18 weeks. Secondary objectives included superiority of dulaglutide over placebo in change from baseline in body weight and fasting serum glucose (FSG) at 18 weeks. Investigational doses of dulaglutide were compared to the 1.5 mg dose as an exploratory objective. Results: HbA1c reduction at 18 weeks was significantly greater with dulaglutide vs placebo (placebo, −0.44% ± 0.10% [−4.8 ± 1.1 mmol/mol]; dulaglutide 1.5 mg, −1.23% ± 0.10% [−13.5 ± 1.1 mmol/mol]; dulaglutide 3.0 mg, −1.31% ± 0.10% [−14.3 ± 1.1 mmol/mol]; dulaglutide 4.5 mg, −1.40% ± 0.10% [−15.3 ± 1.1 mmol/mol]; P < 0.001, each dose), as were changes in body weight (placebo, −1.6 ± 0.39 kg; dulaglutide 1.5 mg, −2.8 ± 0.39 kg; dulaglutide 3.0 mg, −3.9 ± 0.39 kg; dulaglutide 4.5 mg, −4.1 ± 0.41 kg; P < 0.001, each dose). All three dulaglutide doses significantly reduced FSG from baseline (1.5 mg, −36.2 ± 4.7 mg/dL [−2.0 ± 0.3 mmol/L]; 3.0 mg, −34.5 ± 4.5 mg/dL [−1.9 ± 0.3 mmol/L]; 4.5 mg, −38.0 ± 4.7 mg/dL [−2.1 ± 0.3 mmol/L]) vs placebo (−12.4 ± 4.5 mg/dL [−0.7 ± 0.3 mmol/L]) ( P < 0.001, all). Safety profiles of the higher doses were consistent with the established safety profile for dulaglutide. Gastrointestinal events were mostly mild to moderate, and was dose‐related for nausea. Conclusion: All three dulaglutide doses were superior to placebo in improving glycaemic control and reducing body weight in participants with T2D using metformin. The potential for doses of dulaglutide of 3.0 and 4.5 mg to provide additional glycaemic benefit and weight reduction with an acceptable safety profile, compared with the 1.5 mg dose, warrants further study in a phase 3 trial.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/dom.13764

Cites

15 of 15 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 15 references

Cited by

See all 46

Metadata

Authors
Frias, J. P., Wynne, A. G., Matyjaszek‐Matuszek, B., Bartaskova, D., Cox, D. A., Woodward, B., Li, Y. G., Tham, L. S., & Milicevic, Z.
Venue
Diabetes, Obesity and Metabolism
Publisher
Wiley
Published
2019-06-03
Volume
21
Issue
9
Pages
2048-2057
ISSN
  • 1462-8902 (ISSN-L)
  • 1463-1326
OpenAlex
W2943546226
Cited by
46
References
15
FWCI
2.58
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Efficacy and safety of an expanded dulaglutide dose range: A phase 2, placebo‐controlled trial in patients with type 2 diabetes using metformin. https://app.cochat.ai/papers/10.1111/dom.13764
The paper
Frias, J. P., Wynne, A. G., Matyjaszek‐Matuszek, B., Bartaskova, D., Cox, D. A., Woodward, B., Li, Y. G., Tham, L. S., & Milicevic, Z. (2019). Efficacy and safety of an expanded dulaglutide dose range: A phase 2, placebo‐controlled trial in patients with type 2 diabetes using metformin. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/dom.13764

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.